Donation data reported on websites by drug makers and patient advocacy groups in Canada that receive industry funding is ‘haphazard, inconsistent and incomplete,’ underscoring the difficulties in deciphering the influence these companies may have on patient interests, a new analysis finds.
Specifically, information about the value of donations made by drug companies, the years in which contributions were given, and the percent of income the money represented for patient groups was limited. Consequently, donations made and received often could not be matched, according to the analysis in the International Journal of Health Policy and Management. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/pharmalot/2022/01/07/donation-canada-pharmaceutical-transparency
